This is a Phase 2a, open label, proof-of-concept clinical study to assess the efficacy and safety of etrasimod in patients with PG (Pyoderma Gangrenosum).
Pyoderma gangrenosum (PG) causes painful, skin ulcers which can recur and cause scarring.
There is no cure for this condition. Current treatment options include drugs that reduce inflammation, like corticosteroids, and drugs that suppress the immune system.
Etrasimod is an experimental drug, this means that it is not an approved treatment for PG by the Therapeutic Goods Administration (TGA) in Australia, or other parts of the world. This is the first study using Etrasimod in PG and it aims to assess the effectiveness and safety of using Etrasimod in patients with PG.
Participation in the study lasts up to 18 weeks and eight clinic visits will be scheduled. During the treatment period, you will need to take one 2mg tablet of study medication (Etrasimod) by mouth, once daily.
Monetary compensation will be made for the time, travel, and out-of-pocket expenses associated with the study.
Unable to participate in this trial? Register for similar trials.